For example, Salazar et al. in their cohort compared subjects with ANA-positive versus ANA-negative SSc (n=3249), finding that the latter presented notably less cutaneous, pulmonary, and especially vasculopathic involvement [16]. This evidence concerns the gene BTG3 and systemic sclerosis.